159 related articles for article (PubMed ID: 16240877)
21. Treatment of Alzheimer's disease: current and future therapeutic approaches.
Cummings JL
Rev Neurol Dis; 2004; 1(2):60-9. PubMed ID: 16400259
[TBL] [Abstract][Full Text] [Related]
22. [New therapeutic options in Alzheimer's disease].
García-Ruiz Espiga PJ; Echeverría A; García-Torres A; Contreras A
Rev Neurol; 2006 Apr 16-30; 42(8):478-81. PubMed ID: 16625510
[TBL] [Abstract][Full Text] [Related]
23. Future therapeutic approaches to Alzheimer's disease.
Davis KL
J Clin Psychiatry; 1998; 59 Suppl 11():14-6. PubMed ID: 9731545
[TBL] [Abstract][Full Text] [Related]
24. [Is there a treatment for Alzheimer's disease?].
Joray S; Ghika J; von Gunten A; Büla C; Gold G; Assal F
Rev Med Suisse; 2005 May; 1(18):1201-2, 1205-6, 1208. PubMed ID: 15977708
[TBL] [Abstract][Full Text] [Related]
25. The experimental Alzheimer's disease drug posiphen [(+)-phenserine] lowers amyloid-beta peptide levels in cell culture and mice.
Lahiri DK; Chen D; Maloney B; Holloway HW; Yu QS; Utsuki T; Giordano T; Sambamurti K; Greig NH
J Pharmacol Exp Ther; 2007 Jan; 320(1):386-96. PubMed ID: 17003227
[TBL] [Abstract][Full Text] [Related]
26. Acetylcholinesterase inhibitors, neuropsychiatric symptoms, and Alzheimer's disease subtypes: an alternate hypothesis to global cognitive enhancement.
Brousseau G; Rourke BP; Burke B
Exp Clin Psychopharmacol; 2007 Dec; 15(6):546-54. PubMed ID: 18179307
[TBL] [Abstract][Full Text] [Related]
27. Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease.
Martone RL; Zhou H; Atchison K; Comery T; Xu JZ; Huang X; Gong X; Jin M; Kreft A; Harrison B; Mayer SC; Aschmies S; Gonzales C; Zaleska MM; Riddell DR; Wagner E; Lu P; Sun SC; Sonnenberg-Reines J; Oganesian A; Adkins K; Leach MW; Clarke DW; Huryn D; Abou-Gharbia M; Magolda R; Bard J; Frick G; Raje S; Forlow SB; Balliet C; Burczynski ME; Reinhart PH; Wan HI; Pangalos MN; Jacobsen JS
J Pharmacol Exp Ther; 2009 Nov; 331(2):598-608. PubMed ID: 19671883
[TBL] [Abstract][Full Text] [Related]
28. [Medical treatment of Alzheimer's disease].
López-Pousa S; Serra-Mestres J
Rev Neurol; 1998 Jun; 26(154):1054-60. PubMed ID: 9658492
[TBL] [Abstract][Full Text] [Related]
29. Cholinergic and glutamatergic drugs in Alzheimer's disease therapy.
Clarke NA; Francis PT
Expert Rev Neurother; 2005 Sep; 5(5):671-82. PubMed ID: 16162091
[TBL] [Abstract][Full Text] [Related]
30. Alzheimer's disease: from pathology to therapeutic approaches.
Jakob-Roetne R; Jacobsen H
Angew Chem Int Ed Engl; 2009; 48(17):3030-59. PubMed ID: 19330877
[TBL] [Abstract][Full Text] [Related]
31. The new approach in development of anti-Alzheimer's disease drugs via the cholinergic hypothesis.
Sugimoto H
Chem Biol Interact; 2008 Sep; 175(1-3):204-8. PubMed ID: 18577377
[TBL] [Abstract][Full Text] [Related]
32. Powerful beneficial effects of macrophage colony-stimulating factor on beta-amyloid deposition and cognitive impairment in Alzheimer's disease.
Boissonneault V; Filali M; Lessard M; Relton J; Wong G; Rivest S
Brain; 2009 Apr; 132(Pt 4):1078-92. PubMed ID: 19151372
[TBL] [Abstract][Full Text] [Related]
33. Treatment of Alzheimer's disease: from pharmacology to a better understanding of disease pathophysiology.
Silvestrelli G; Lanari A; Parnetti L; Tomassoni D; Amenta F
Mech Ageing Dev; 2006 Feb; 127(2):148-57. PubMed ID: 16278007
[TBL] [Abstract][Full Text] [Related]
34. Progress in Alzheimer's disease drug discovery: an update.
Williams M
Curr Opin Investig Drugs; 2009 Jan; 10(1):23-34. PubMed ID: 19127484
[TBL] [Abstract][Full Text] [Related]
35. Development of anti-Abeta vaccination as a promising therapy for Alzheimer's disease.
Okura Y; Matsumoto Y
Drug News Perspect; 2007; 20(6):379-86. PubMed ID: 17925892
[TBL] [Abstract][Full Text] [Related]
36. [Pharmacological treatment of Alzheimer's disease].
Donoso A
Rev Med Chil; 1991 Apr; 119(4):452-7. PubMed ID: 1842993
[TBL] [Abstract][Full Text] [Related]
37. Treatment strategies for the cognitive deficits of Alzheimer's disease.
Meador KJ
J S C Med Assoc; 1994 Nov; 90(11):543-7. PubMed ID: 7853858
[No Abstract] [Full Text] [Related]
38. Acetylcholinesterase inhibitors for Alzheimer's disease: anti-inflammatories in acetylcholine clothing!
Tabet N
Age Ageing; 2006 Jul; 35(4):336-8. PubMed ID: 16788077
[TBL] [Abstract][Full Text] [Related]
39. Molecular pathology and pharmacogenomics in Alzheimer's disease: polygenic-related effects of multifactorial treatments on cognition, anxiety and depression.
Cacabelos R
Methods Find Exp Clin Pharmacol; 2007 Jul; 29 Suppl A():1-91. PubMed ID: 17957277
[TBL] [Abstract][Full Text] [Related]
40. Neuropathologic changes in Alzheimer's disease: potential targets for treatment.
Wenk GL
J Clin Psychiatry; 2006; 67 Suppl 3():3-7; quiz 23. PubMed ID: 16649845
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
